An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Summary

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.

Timeline

Start

2020-07-14

Primary completion

2024-10-09

Completion

2025-03-11

Publications

• Bove R, Langdon D, Maciejowski M, Jasinska E, Dufek M, Abeyewickreme A, Rauh A, Fu H, Khan IA, Bohringer M, Eichau SM, Derfuss T. Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study. J Neurol. 2026 Jun 29;273(7):434. doi: 10.1007/s00415-026-13960-5.

Drugs

Indications